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19%. To date, follow-up angiographic and IVUS volumetric analysis was performed in 17 
lesions and the results are showed in the table bellow. There were no cardiac Or drug- 
related adverse clinical events. 
PROXIMAL STENT DISTAL 
EDGE EDGE 
MLD (mm) 2.74*0.79 2.61*0.68 2.84*0.48 
Late Loss (mm) 0.47 0,52 0,19 
Restenosis Rate % (>50%DS) 5.9 5.9 0 
Lumen Volume (mm3) 33.3+11.6 115.1*46.9 35.6t8.7 
lntimal Hyperplasia Volume (mm3) 6.7 15.5 1.4 
lntimal Hyperplasia (% of volume) 16.7 11.8 3,7 
Hyperplasia Index (mmYmm) 1,3 0,97 0,2 
Conclusions: Oral Sirolimus treatment during 14 days showed to be safe without car- 
diac or drug-related adverse events. Angiographic and IVUS volumetric analysis suggest 
that adjunct oral Sirolimus decrease neointimal hyperplasia after Stem implantation in 
denovo coronary lesions 
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1075MP-170 Bivalirudin Reduces lschemic and Hemorrhagic 
Complications of Percutaneous Coronary Intervention: 
Pooled Data From 10 Prospective Studies in 6,134 
Patients 
Frederick Feit, John A. Bittl, A. Michael Lincoff, Derek P. Chew, Neal S. Kleiman, Lars 
Wallentin. Harvey D. White, John Omiston, Richard Robson, Philip E. Aylward, Michael 
J. Attubato, New York University School of Medicine, New York, NY, The Cleveland 
Clinic Foundation, Cleveland, OH 
Background: Bivalirudin is a thrombin-specific anticoagulant approved for use in angio- 
plasty. Recent studies have evaluated the use of bivalirudin with GP Ilb/llla inhibitors and 
stents. We combined the entire reported clinical trial experience for bivalirudin vs. hep- 
arin in percutaneous coronary intetventlon (PCI). 
Methods: Ten prospective PCI studies performed between 1993 and 2001 were 
included in the analvs~s. A Sinale data set was built usina common data fields and 
descriptions of vanables. Bivalirudin and heparin were given at a range of doses consis- 
tent with the standard of care at the time. Thienoovridines were aiven in 8 studies: GPllb/ 
I  
llla inhibitors in 6 studies. Myocardlal infarction (Ml) was generally defined as CK-MB > 
3x normal and hemorrhage as a > 3g/dl decrease in hemoglobin. 
Results: A total of 6,134 patients, median age 63 yrs, 70% male, were treated with biva- 
lirudin (n=3,277) or heparin (“~2,857). The results for the ischemic (death, MI. target ves- 
sel revascularization (TVR)) and hemorrhagic endpoints within seven days are shown in 
the table. 
Conclusions: In this analysis of IO prospective PCI trials, bivalirudin reduced the triple 
lschemic endpoint of death, MI, TVR by 24% (p=O.O03) and reduced hemorrhage by 63% 
(p<O.OOOl). Thus, bivalirudin is superior to heparin in preventing both ischemic and hem- 
orrhaglc complications in a broad population of patients undergoing PCI. 
All PC1 Trials nz6.134 
Bivalirudin (n=3,277) Heparin (n=2,857) 
n (%) n (%) 
Any event 241 (7.4) 372 (13.0) 
Death/MI/TVR 186 (5.7) 215 (7.5) 
Death/Ml 113 (3.4) 127 (4.4) 
Death 7 (0.2) 8 (0.3) 
Ml 109 (3.3) 124 (4.3) 
NR 107 (3.3) 137 (4.8) 
Hemorrhage 91 (2.8) 217 (7.6) 
p-value 
<0.0001 
0.003 
0.045 
0.599 
0.038 
0.002 
<0.0001 
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1075MP-171 Excessive Body Weight Does Not Increase the Risk of 
Complications Following Percutaneous Coronary 
Interventions 
Abel E. Morevra, Ajay K. Agarwala, Kenneth Khaw, Natalie Socha, Alan C. Wilson, 
UMDNJ-Roben Wood Johnson Medical School, New Brunswick, NJ 
Background: Excessive body weight (BMI) has been reported as a risk factor for compli- 
cations following percutaneous coronary interventions (PCI). However, recent significant 
technological advances in PCI have prompted a re-examination of this association to 
study the association of exceswe BMI with increased complications of PCI. 
Methods: A university hospital database of 9,537 consecutive patients undergoing PCI 
was analyzed. The International Obesity Task Force classifwtion was used. 
Results: There were no significant differences in the rates of success, emergency 
bypass surgery (CABG), transfusion, or bleeding complications between the BMI 
classes. Healthy weight patients had a higher In-hospital death rate (1.8%, p=O.O03) 
compared to the other BMI classes. After adjusting for demographic and procedural vari- 
ables with multivariate analysis, BMI had no independent association with PCI complaa- 
tions. 
Conclusion: In contrast with previous reports, excessive BMI (>35) was not found to be 
a risk factor for death or major complications of PCI. Although bleeding complications 
were higher among patients with higher BMI, the incidence rate was lower than previ- 
ously reported. We conclude that these favorable results may be due to new technolo- 
gies and improved anticoagulation approaches. 
PC1 Outcomes by BMI Class 
Healthy Overweig Obese 1 Obese Obese P 
18.5to ht 30to 2 3 Value 
<25 25 to ~30 <35 35 > 40 
to<40 
N 2,259 4,188 2,049 739 302 - 
Success Rate, % 96 96 96 96 95 NS 
Death, % 1.8 1.0 0.7 0.8 0.7 0.003 
Emergency CABG, % 1.1 0.7 1.2 0.8 1.5 NS 
Bleeding Complication, 1.9 0.8 1.4 1.6 2.6 NS 
% 
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1075MP-172 Kinetics of Intravenously Administered Dalteparin 
Chad C. Schoolev Jerry H. Gilbert, Mary Harlan, Arthur Bracey, Stephanie Coulter, 
James M. Wilson, Baylor College of Medicine, Houston, TX, Texas Heart Institute, 
Houston, TX 
Background: Outcomes using low molecular weight heparins for unstable angina and 
myccardial infarction have stimulated interest in their use during percutaneous coronary 
intewention (PCI). To define drug-dose response and clearance, we measured the anti- 
Xa activity at fixed time points after IV bolus dosing of dalteparin. 
Methods:20 medication-free volunteers (10 male, 10 female) with normal renal function 
were treated at 2 week intervals with each of 3 dalteparin doses (40, 60, and 80 IU/kg). 
Using a peripheral IV catheter, anti-Xa and anti-lla activities were measured at baseline, 
5, 15. 30, 45, 60, 240. and 480 minutes after the IV administration of dalteparin. Single 
exponential modeling was used to calculate the effective half-life (r1,28) for indivtduals 
and examine the effect of dose. The simplified MDRD formula was used to calculate 
glomerular filtration rate (GFR). 
FteeuI1B: Subjects had a mean age of 35 *4 years and mean weight of 77 +lOkg with 
GFR of 92*15 ml/min. The peak anti-Xa and anti-lla activities, T,,,. of anti-Xa activity 
after a single administration, terminal half-life of anti-Xa activity, and clearance values 
are listed below. The volume of distribution (Vd) was 41 210 ml/kg. The TIiPe was similar 
for 40 and 60 IU/kg. but was longer after a dose of 80 IUikg (p=O.O09). There was no cor- 
relation between T,i2. and GFR. 
Conclusiorr The pharmacokinetics of dalteparin I” normal individuals are described. 
These results will assist in the design of trials of dalteparin anticoagulation during PCI. 
Anti-Xa Activity Effective Tl/Z Terminal Tl12 Clearance 
(U/ml) (min) (min) (mllmin) 
40 1u/kg 1.07 64 107 25 
60 IUlkg 1.53 65 103 23 
80 IU/kg 1.83 82 128 29 
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1076-l 84 Left Ventricular Function in the Stent or Surgery Trial 
One Year After Randomization to Coronary Artery 
Bypass Graft Surgery or Stent Percutaneous Coronary 
Intervention 
Georae Koutroulis Marina Flitsou, Jean Booth, Tim Clayton, Rod H. Stables, Fiona 
Nugara, Petros Nihoyannopoulos. Hammersmith Hospital, NHLI, ICSM. London, United 
Kingdom, Royal Brompton Hospital, London, United Kingdom 
Background: In the Stem or Surgery study, we prospectively randomlsed 500 pattents to 
coronary artery bypass graft surgery (CABG) and 488 patients to stenting percutaneous 
coronary intervention (PCI), for optlmal revascularisation. We hypothesised that left ven- 
tricular (LV) function at 1 year post procedure wll be the same, regardless the initial 
treatment allocation. 
Methods: Global LV function was assessed by eJection fraction (EF, biplane modified 
Simpson’s rule), and reglonal LV function by the wall motion score index (WMSI, Ameri- 
can Society of Echocardiography), using echocardiography. Echocardiographic studies 
were analysed blindly at a core laboratory Primary outcome was a comparison of WMSI 
